foot shows increased heel pad thickness. CXR revealed cardiomegaly with scoliosis. Echocardiography showed systolic dysfunction with E.F 40% with moderate mitral regurgitation. After confirmation of the diagnosis of acromegaly due to pituitary microadenoma transsphenoidal endoscopic pituitary surgery was done following stabilization of cardiac function. After successful surgery tissue was sent for histopathology which showed pituitary neoplasm composed of fairly uniform polygonal cells arranged in sheets. The cells had abundant eosinophilic cytoplasm and supporting connective tissue stroma was scarce. Post operative growth hormone level came down to normal with uneventful postoperative recovery. The patient was discharged at home on 9 th post operative day. 
Discussion:
Acromegaly is a consequence of chronic growth hormone (GH) excess, due in the majority of cases to a GH-secreting pituitary adenoma, and occurring with a population prevalence of 60 per million and an incidence of 3-4 per million per year 1 . Males and females appear to be equally affected with an average age of presentation of 44 years 1 .
Considerable evidence suggests acromegaly can cause specific type of cardiomyopathy which can result in structural and functional abnormalities resulting in heart failure. This may be partially reversed by effective reduction in GH and IGF-1 levels 2, The patient in this report had massive cardiomegaly with a cardiothoracic ratio of <0.9. In acromegaly, cardiac enlargement is a consistent finding and seems to be disproportionate, compared with the increase in size of other internal body organs. 2 An increased frequency of systemic hypertension and premature coronary artery disease have also been described. 2 Epidemiological study showed that in patients with acromegaly, valvular abnormalities are more prevalent than in control subjects, who were individually matched for left ventricular function, age, sex, and the presence of hypertension 3 . In addition, it has been found that in acromegalic cardiomyopathy myocardial hypertrophy with interstitial fibrosis, lymphomononulear infiltration, and areas of monocyte necrosis resembling myocarditis are prominent histopathological features. These changes often result in increased left ventricular mass and concentric hypertrophy. 2, 4 Left ventricular hypertrophy occurs first, often leading to slow deterioration of diastolic function early in the disease. 5, 6 This finding has been reported in acromegalic patients even with disease duration shorter than five years. 7.8 Our patient developed overt heart failure at the age of 70 years with clinical features of acromegaly for almost seven years. Then she suddenly developed heart failure.
Clinically evident congestive heart failure may develop when the disease is untreated or unsuccessfully treated. 7 Our patient sought medical attention because of severe symptoms of congestive heart failure. Data are limited on clinically evident heart failure in acromegalics. Damganovics et al reported high-output failure in 10% of patients, while Hayward et al found only 7 out of 256 patients (<1%) with clinically evident heart failure. 9.10 Echocardiographic findings in this patient showed significant increase in end-systolic and end-diastolic dimensions, reduction in the ejection fraction and fractional shorting, and reversal of the E/A ratio, in the presence of severe signs of congestive heart failure. These echocardiographic features have been documented in young acromegalics without any clinical evidence of cardiac impairment. 7 Cardiac dysrhythmias have been documented in a few reports, due to the left ventricular remodeling that occur in this disease. 11, 12 However, our patient did not present with any form of ventricular arrythmia. In the absence of other causes of heart failure and mitral regurgitation in this case, we think that her heart failure was caused by acromegalic cardiomyopathy, although we couldn't confirm it by myocardial biopsy.
Treatment of acromeagly presenting with heart failure is aimed at removing the source of GH hyper secretion or at suppressing its activity along with other supportive treatment for heart failure. Somatostatin analogues are effective as first-line therapy and have a success rate of 45%-65%. 13, 14. Besides this, surgery and local irradiation are other options of treatment. Our patient was, however, treated surgically which made a good symptomatic recovery of her heart failure.
Conclusion:
Though classically acromegaly patients commonly presents with progressive enlargement of limbs and coarsening of faces but rarely it may present with obvious heart failure caused by cardiomyopathy. So we need to look for endocrine cause of heart failure like acromegaly when there is no other overt cause of failing heart.
